Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 5.67M | $104.0M | 10.42% | -- | 2026-06-30 |
| FMR LLC | 4.93M | $90.0M | 9.06% | +3.39M | 2026-06-30 |
| FCPM III SERVICES B.V. | 4.12M | $75.0M | 7.56% | -- | 2026-06-30 |
| BlackRock, Inc. | 3.47M | $63.0M | 6.37% | +2.67M | 2026-06-30 |
| Venrock Adviser, LLC | 3.04M | $55.0M | 5.59% | -- | 2026-06-30 |
| STATE STREET CORP | 2.62M | $48.0M | 4.80% | +1.50M | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | 2.54M | $46.0M | 4.67% | -- | 2026-06-30 |
| RA CAPITAL MANAGEMENT, L.P. | 2.40M | $44.0M | 4.41% | -3.00M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.08M | $38.0M | 3.83% | +651.0K | 2026-06-30 |
| Caligan Partners LP | 1.93M | $35.0M | 3.54% | -- | 2026-06-30 |
